Drug Topics - November 10, 2008 - (Page 50)

Clinical New Products Rx Care New Drug Covidien launches TussiCaps Extended Release Capsules (hydrocodone polistirex/chlorpheniramine polistirex). TussiCaps, for cough suppression, is the only extended-release capsule formula that contains hydrocodone and chlorpheniramine, providing powerful cough suppression for up to 12 hours. According to the manufacturer, this new product, which contains a consistent dose of the medication, offers more precise and convenient dosing than liquid formulations. For more information visit www.covidien.com or call 441-2982480. Coria Laboratories Ltd. has launched Tetrix Cream [1] for the management of various dermatoses. Tetrix Cream is a nonsterile cream formulation that has demonstrated its effectiveness in clinical trials as a barrier to irritants and allergens such as nickel sulfate, neomycin, a mixture of fragrances, and/or lactic acid. Tetrix Cream offers dermatologists a new modality with which to manage the burning and itching associated with various commonly seen dermatoses, such as chronic hand dermatitis. The cream is designated as a 510K device by the U.S. Food and Drug Administration (FDA). For more information, visit www.tetrixcream.com or call (866) 819-9007. DizzyFIX has been approved for sale in the United States by FDA. Made in Canada by Clearwater, DizzyFIX is an at-home treatment for vertigo and dizziness that helps guide patients through the Epley maneuver. According to its manufacturer, DizzyFIX will now be OTC Prestige Brands Holdings Inc. announces the launch of Chloraseptic Allergen Block and Little Allergies Allergen Block [2]. According to the company, these OTC products prevent nasal allergy symptoms by blocking allergens in the air on contact, before they enter the nasal passages. Topical gels that are applied around the outside of the nostrils to block both indoor and out door airborne allergens, they are sold at drug stores, mass merchandisers, and supermarkets. For more information on Allergen Block, visit www.allergenblock.com. Oregon Aesthetic Technologies announces the availability of ANSR: Acne Care [3], an acne treatment featuring clinically-proven phototherapy and topical ingredients to ﬁght acne and heal the skin. Its manufacturer calls ANSR: Acne Care an evolutionary shift in athome skin care, pointing to its use of phototherapy technology and powerful patent-pending topicals to build a comprehensive skin-care solution that addresses multiple causes and effects of acne, including excess skin-surface debris, oiliness, pore-clogging sebum, bacteria, inflammation, redness, and scarring. See www.ANSR.com for more information. W W W.D R U GTO P I C S .C O M 50 DRUG TOPICS N OV. 10, 2008 COURTESY OF CORIA LABORATORIES LTD, PRESTIGE BRANDS HOLDINGS INC, OREGON AESTHETIC TECHNOLOGIES available by prescription in the United States. A low-cost, patent-pending dynamic visual-feedback device that easily attaches to a hat, DizzyFIX is geared to patients with benign paroxysmal positional vertigo (BPPV), one of the leading causes of dizziness, which affects as many as 10 percent of people older than 60. To learn more about DizzyFIX, visit DizzyFIX.com or call (877) 349-9934. Sanoﬁ-Aventis announced that the FDA has approved Nasacort AQ Nasal Spray (triamcinolone acetonide) for children ages 2 to 5 for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis. Contact Sanofi-Aventis at (908) 981-6563. http://www.covidien.com http://www.DizzyFIX.com http://www.allergenblock.com http://www.allergenblock.com http://www.tetrixcream.com http://www.ANSR.com http://WWW.DRUGTOPICS.COM

Table of Contents Feed for the Digital Edition of Drug Topics - November 10, 2008

Drug Topics - November 10, 2008 Contents Up Front Up Front in Depth Letters Rx Care Government Community Practice First Responders Clinical Practice Self-Care FDA Safety Page Weighing the Complications of Obesity New Products Viewpoint

Drug Topics - November 10, 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.